We do see something of ourselves in the eyes of someone who has just died. We see the fragility of life and of human connections. We see our own mortality. But there are physicians in Southern Africa and other epicenters of the pandemic who look into the eyes of thousands of children dying unnecessarily from lack of access to AIDS drugs. Watching a child die is a difficult challenge to physicians. The difficulty increases when the physician knows that such death is unneccesary.
Each time that a child dies unnecessarily from AIDS, the physician is reminded that no one in the world believed that the child's life was worth the few thousand dollars each year that it would take to purchase the drugs. The physician is reminded that there was no one willing to underwrite the costs to train that physician on how to use these life-saving drugs if they were available. The physician is reminded that this child may not have become infected if there was a commitment to support the education, counseling, drugs, and diagnostics to reduce mother-to-child transmission of HIV. The physician is reminded that it would take, in relative terms, only a few coins to save a child's life -- coins better spent to keep a child alive than to place over the eyelids of the dead.
But before such coins can be gathered, there must be respect for the dignity and value of African lives. It is only out of such respect that the obligation arises to help those who will die without such help. Charles Heimbold, Jr., chairman and CEO of BMS and his project team that have crafted Secure the Future are giving the people of Southern Africa much more than a $100 million commitment. They have given the people of Botswana, Lesotho, Namibia, South Africa, and Swaziland the respect that is due them.
We are defined not by what we say, but by what we do. If we are apathetic about the AIDS pandemic in Africa, it is because we do not respect the dignity and value of African lives. The enemy is not HIV. The enemy is our arrogance. Secure the Future challenges our arrogance. The real test of whether Secure the Future works, is not the number of lives that are saved or lengthened, or even if the programs are sustainable, the real test is whether other pharmaceutical companies, corporations, institutions, communities of faith, and each of us individually demonstrate our respect for the value and dignity of each person living on the African continent by some palpable action.
The essential element of successful leadership is the ability to motivate others to follow. Secure the Future as a program will be evaluated from many different perspectives. But Secure the Future will also be measured by its impact on other pharmaceutical manufacturers, the corporate community, communities of faith, and you and me -- how we are motivated to respond to the challenge of AIDS in Africa.
Gordon Nary is the Editor of the Journal.